LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Regulus Therapeutics Inc

Cerrado

8.21 1.36

Resumen

Variación precio

24h

Actual

Mínimo

8.01

Máximo

8.27

Métricas clave

By Trading Economics

Ingresos

3.2M

-9.6M

Ventas

340K

340K

BPA

-0.15

Margen de beneficios

-2,833.529

Empleados

34

EBITDA

2.2M

-11M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 Meses

+8.64% upside

Dividendos

By Dow Jones

Próximas Ganancias

6 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

315M

550M

Apertura anterior

6.85

Cierre anterior

8.21

Regulus Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

30 abr 2025, 16:35 UTC

Principales Movimientos del Mercado
Adquisiciones, fusiones, absorciones

Regulus Shares Surge on $1.7 Billion Acquisition by Novartis

30 abr 2025, 11:55 UTC

Adquisiciones, fusiones, absorciones

Novartis to Acquire MicroRNA-Technology Specialist Regulus for Up to $1.7 Billion

30 abr 2025, 11:54 UTC

Adquisiciones, fusiones, absorciones

Novartis to Acquire Regulus in $1.7 Billion Deal

27 may 2025, 12:04 UTC

Adquisiciones, fusiones, absorciones

Correct: Novartis Will Offer $7.00 in Cash Per Share

27 may 2025, 12:01 UTC

Adquisiciones, fusiones, absorciones

Novartis: Offer Will Expire on June 24

27 may 2025, 12:00 UTC

Adquisiciones, fusiones, absorciones

Novartis Will Offer $0.001 Per Share

27 may 2025, 11:59 UTC

Adquisiciones, fusiones, absorciones

Novartis: Offer Is to Acquire All Outstanding Shares of Regulus Therapeutics's Common Stock

27 may 2025, 11:59 UTC

Adquisiciones, fusiones, absorciones

Novartis: Redwood Merger Sub Inc. Is an Indirect Wholly Owned Subsidiary of Novartis

27 may 2025, 11:58 UTC

Adquisiciones, fusiones, absorciones

Novartis: Redwood Merger Sub Inc. Has Commenced a Tender Offer

27 may 2025, 11:57 UTC

Adquisiciones, fusiones, absorciones

Novartis Announces Commencement of Tender Offer to Buy Regulus Therapeutics

30 abr 2025, 11:40 UTC

Adquisiciones, fusiones, absorciones

Novartis to Acquire MicroRNA-Technology Specialist Regulus for Up to $1.7 Bln

30 abr 2025, 11:39 UTC

Adquisiciones, fusiones, absorciones

Novartis to Acquire Regulus in $1.7B Deal

30 abr 2025, 11:16 UTC

Adquisiciones, fusiones, absorciones

Novartis: Transaction Is Expected to Close in Second Half of 2025

30 abr 2025, 11:15 UTC

Adquisiciones, fusiones, absorciones

Novartis: Regulus Therapeutics Is U.S. Biotech Focused on microRNA Therapeutics

30 abr 2025, 11:14 UTC

Adquisiciones, fusiones, absorciones

Novartis: Transaction Includes USD0.8B Upfront Payment, Potential Additional USD 0.9B Payment

30 abr 2025, 11:13 UTC

Adquisiciones, fusiones, absorciones

Novartis to Buy Regulus Therapeutics

Comparación entre iguales

Cambio de precio

Regulus Therapeutics Inc previsión

Precio Objetivo

By TipRanks

8.64% repunte

Estimación a 12 Meses

Media 8.8 USD  8.64%

Máximo 11 USD

Mínimo 7 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Regulus Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

6 ratings

1

Comprar

5

Mantener

0

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Regulus Therapeutics Inc

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.